Solriamfetol 75mg, 150 mg, or 300 mg
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Binge-Eating Disorder
Conditions
Binge-Eating Disorder
Trial Timeline
Feb 20, 2025 → Dec 1, 2026
NCT ID
NCT06878976About Solriamfetol 75mg, 150 mg, or 300 mg
Solriamfetol 75mg, 150 mg, or 300 mg is a phase 3 stage product being developed by Axsome Therapeutics for Binge-Eating Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06878976. Target conditions include Binge-Eating Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06878976 | Phase 3 | Recruiting |
Competing Products
3 competing products in Binge-Eating Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo | Novo Nordisk | Phase 3 | 76 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| ACT-539313 + Placebo | Idorsia | Phase 2 | 47 |